Astria Therapeutics, Inc. $ATXS Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its position in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 4,607.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,696,071 shares of the biotechnology company’s stock after buying an additional 1,660,039 shares during the quarter. JPMorgan Chase & Co. owned 3.01% of Astria Therapeutics worth $9,091,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ATXS. Farther Finance Advisors LLC increased its position in shares of Astria Therapeutics by 185.8% during the second quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,557 shares during the last quarter. Wellington Management Group LLP grew its stake in Astria Therapeutics by 3.1% during the 1st quarter. Wellington Management Group LLP now owns 152,611 shares of the biotechnology company’s stock valued at $815,000 after purchasing an additional 4,562 shares in the last quarter. AlphaQuest LLC increased its holdings in Astria Therapeutics by 100.9% during the 1st quarter. AlphaQuest LLC now owns 14,216 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 7,139 shares during the last quarter. Brooklyn Investment Group raised its position in shares of Astria Therapeutics by 1,079.6% in the 1st quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 7,957 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Astria Therapeutics by 22.1% during the 1st quarter. American Century Companies Inc. now owns 52,107 shares of the biotechnology company’s stock valued at $278,000 after buying an additional 9,414 shares during the last quarter. 98.98% of the stock is owned by hedge funds and other institutional investors.

Astria Therapeutics Trading Down 0.4%

Shares of NASDAQ ATXS opened at $12.95 on Wednesday. Astria Therapeutics, Inc. has a 12-month low of $3.56 and a 12-month high of $13.29. The company has a market cap of $739.19 million, a price-to-earnings ratio of -6.05 and a beta of 0.07. The stock’s 50 day simple moving average is $11.67 and its 200 day simple moving average is $8.23.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The business had revenue of $0.71 million during the quarter, compared to analysts’ expectations of $10.67 million. As a group, equities analysts forecast that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ATXS has been the subject of a number of research analyst reports. Evercore ISI restated an “outperform” rating and issued a $26.00 price target on shares of Astria Therapeutics in a research note on Wednesday, October 1st. Lifesci Capital lowered shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Astria Therapeutics in a research report on Wednesday, October 8th. Citigroup reaffirmed an “outperform” rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. Finally, Wedbush set a $13.00 price target on Astria Therapeutics and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Two investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $24.50.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.